Monday 16 September 2019
12:00-12:15  Opening
12:15-13:45

  Session I: Pre-clinical development I
INV01: Michael Hudecek (University of Würzburg)
INV02: Hinrich Abken (University Hospital Cologne)
OR1
OR2

13:45-14:00 Comfort break
14:00-15:30

Session II: Pre-clinical development II
INV03: Michael Bachmann (Helmholtz Center Dresden Rossendorf)
INV04: Chiara Bonini (San Raffaele Hospital, Milan)

First choice alternatives: Gerald Willimsky (Charité, Berlin), Angela Krackhardt (Technical University Munich) in session I or II
Second alternatives: Andrew Sewell (University of Cardiff), Marcel v.d. Brink (Sloan Kettering, NY), Luca Gattinoni (NIH, Bethesda)
OR3
OR4

15:30-16:00 Coffee break
16:00-18:00

Session III: Vector production and manufacturing
INV05: Klaus Kühlcke (BioNTech, Mainz)
INV06: Kai Pinkernell (Medigene, Planegg)
INV07: Marco Ruella (UPenn)
INV08: Ulrike Köhl (Fraunhofer Institute Leipzig)
Alternatives: Farzin Farzaneh (King's College London)
OR05
OR06

18:30-22:00 Networking reception and guided tour
 
Tuesday 17 September 2019
09:00-10:30

Session IV: Regulation
INV09: ?? (Paul Ehrlich Institute, Langen)
INV10: Cornelie Haag (Technical University Dresden)
INV11: Nina Worel (Medical University of Vienna)
Regulatory roundtable with session speakers, local clinicians and ethics speaker

10:30-11:00 Coffee break
11:00-13:00

              Session V: Clinical studies I
INV12: John Maher (King's College London)
Pan-ErbB CAR T-cell immunotherapy of head and neck cancer: phase I clinical trial
INV13: Stephan Mielke (Karolinska Institute, Stockholm)
INV14: Hans Stauss (University College London)

Alternatives: Michael Burger (Fraunhofer Institute, Kaiserslautern), Hanno Glimm (NCT, Dresden), Martin Hildebrandt (Technical University Munich), Hildegard Greinix (Medical University Graz)
OR07
OR08

13:00-14:15 Lunch and poster session
14:15-14:45

Keynote: Ethics of CAR-T cells
INV15: Christiane Woopen (Cologne)

14:45-17:15

Session VI: Clinical studies II
INV16: Christos Georgiadis  (University College London)
INV17: Winfried Wels (Georg Speyer Haus, Frankfurt)
CAR-engineered NK cells: off-the-shelf therapeutics bridging innate and adaptive immunity
INV18: Peter Borchmann (University Hospital Cologne) alt Peter Bader (University Hospital Frankfurt)
Alternatives: Rupert Handgretinger (University Hospital Tübingen)
OR09
OR10

17:15-17:45 Closing drinks